Relmada Therapeutics Stock Market Value
| RLMD Stock | USD 0.37 0.05 11.90% |
| Symbol | Relmada |
Relmada Therapeutics Price To Book Ratio
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Relmada Therapeutics. If investors know Relmada will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Relmada Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.86) | Return On Assets (0.59) | Return On Equity (1.00) |
The market value of Relmada Therapeutics is measured differently than its book value, which is the value of Relmada that is recorded on the company's balance sheet. Investors also form their own opinion of Relmada Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Relmada Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Relmada Therapeutics' market value can be influenced by many factors that don't directly affect Relmada Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Relmada Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Relmada Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Relmada Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Relmada Therapeutics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Relmada Therapeutics' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Relmada Therapeutics.
| 11/14/2024 |
| 12/14/2024 |
If you would invest 0.00 in Relmada Therapeutics on November 14, 2024 and sell it all today you would earn a total of 0.00 from holding Relmada Therapeutics or generate 0.0% return on investment in Relmada Therapeutics over 30 days. Relmada Therapeutics is related to or competes with Emergent Biosolutions, Bausch Health, Neurocrine Biosciences, Teva Pharma, Haleon Plc, Intracellular, and Catalent. Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treat... More
Relmada Therapeutics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Relmada Therapeutics' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Relmada Therapeutics upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.20) | |||
| Maximum Drawdown | 90.79 | |||
| Value At Risk | (11.90) | |||
| Potential Upside | 6.1 |
Relmada Therapeutics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Relmada Therapeutics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Relmada Therapeutics' standard deviation. In reality, there are many statistical measures that can use Relmada Therapeutics historical prices to predict the future Relmada Therapeutics' volatility.| Risk Adjusted Performance | (0.13) | |||
| Jensen Alpha | (2.03) | |||
| Total Risk Alpha | (3.42) | |||
| Treynor Ratio | 4.76 |
Relmada Therapeutics Backtested Returns
Relmada Therapeutics maintains Sharpe Ratio (i.e., Efficiency) of -0.18, which implies the firm had a -0.18% return per unit of risk over the last 3 months. Relmada Therapeutics exposes twenty-two different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please check Relmada Therapeutics' Coefficient Of Variation of (526.83), variance of 117.92, and Risk Adjusted Performance of (0.13) to confirm the risk estimate we provide. The company holds a Beta of -0.44, which implies possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning Relmada Therapeutics are expected to decrease at a much lower rate. During the bear market, Relmada Therapeutics is likely to outperform the market. At this point, Relmada Therapeutics has a negative expected return of -2.01%. Please make sure to check Relmada Therapeutics' potential upside, as well as the relationship between the daily balance of power and price action indicator , to decide if Relmada Therapeutics performance from the past will be repeated at some point in the near future.
Auto-correlation | 0.71 |
Good predictability
Relmada Therapeutics has good predictability. Overlapping area represents the amount of predictability between Relmada Therapeutics time series from 14th of November 2024 to 29th of November 2024 and 29th of November 2024 to 14th of December 2024. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Relmada Therapeutics price movement. The serial correlation of 0.71 indicates that around 71.0% of current Relmada Therapeutics price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.71 | |
| Spearman Rank Test | 0.32 | |
| Residual Average | 0.0 | |
| Price Variance | 1.33 |
Relmada Therapeutics lagged returns against current returns
Autocorrelation, which is Relmada Therapeutics stock's lagged correlation, explains the relationship between observations of its time series of returns over different periods of time. The observations are said to be independent if autocorrelation is zero. Autocorrelation is calculated as a function of mean and variance and can have practical application in predicting Relmada Therapeutics' stock expected returns. We can calculate the autocorrelation of Relmada Therapeutics returns to help us make a trade decision. For example, suppose you find that Relmada Therapeutics has exhibited high autocorrelation historically, and you observe that the stock is moving up for the past few days. In that case, you can expect the price movement to match the lagging time series.
Current and Lagged Values |
| Timeline |
Relmada Therapeutics regressed lagged prices vs. current prices
Serial correlation can be approximated by using the Durbin-Watson (DW) test. The correlation can be either positive or negative. If Relmada Therapeutics stock is displaying a positive serial correlation, investors will expect a positive pattern to continue. However, if Relmada Therapeutics stock is observed to have a negative serial correlation, investors will generally project negative sentiment on having a locked-in long position in Relmada Therapeutics stock over time.
Current vs Lagged Prices |
| Timeline |
Relmada Therapeutics Lagged Returns
When evaluating Relmada Therapeutics' market value, investors can use the concept of autocorrelation to see how much of an impact past prices of Relmada Therapeutics stock have on its future price. Relmada Therapeutics autocorrelation represents the degree of similarity between a given time horizon and a lagged version of the same horizon over the previous time interval. In other words, Relmada Therapeutics autocorrelation shows the relationship between Relmada Therapeutics stock current value and its past values and can show if there is a momentum factor associated with investing in Relmada Therapeutics.
Regressed Prices |
| Timeline |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Relmada Therapeutics is a strong investment it is important to analyze Relmada Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Relmada Therapeutics' future performance. For an informed investment choice regarding Relmada Stock, refer to the following important reports:Check out Relmada Therapeutics Correlation, Relmada Therapeutics Volatility and Relmada Therapeutics Alpha and Beta module to complement your research on Relmada Therapeutics. For information on how to trade Relmada Stock refer to our How to Trade Relmada Stock guide.You can also try the Fundamental Analysis module to view fundamental data based on most recent published financial statements.
Relmada Therapeutics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.